A breakthrough in regenerative medicine indicates that a nasal spray could potentially reverse the cognitive decline and chronic brain inflammation associated with aging.
The study, published in the Journal of Extracellular Vesicles, found that scientists at Texas A&M University College of Medicine were able to significantly reduce age-related brain inflammation and improve memory in mice using just two doses of an innovative therapy.
Led by Dr. Ashok Shetty, a university distinguished professor and associate director of the Institute for Regenerative Medicine, the team focused on a phenomenon known as “neuroinflammaging,” a term used to describe the chronic, low-grade inflammation that develops in the brain over time and is associated with cognitive decline.
“Aging is associated with reduced ability to adapt to new stimuli and cognitive decline in a significant proportion of individuals,” the study notes. “Studies using animal models and human post-mortem brain tissues have suggested that cognitive impairments associated with aging are often connected to various adverse changes in the brain, particularly in the hippocampus. The age-related changes include increased oxidative stress, mitochondrial dysfunction, and neuroinflammaging.”
The secret to the treatment lies in “extracellular vesicles” (EVs), microscopic particles derived from neural stem cells that can carry therapeutic molecules. Because of their small size, these vesicles can bypass the blood-brain barrier, a major obstacle in delivering drugs to the brain.
By administering these EVs through a nasal spray, the researchers were able to deliver a payload of therapeutic microRNAs directly into the hippocampus, the area of the brain responsible for memory and learning.
In laboratory trials involving aged mice, the results were dramatic. After receiving only two doses of the spray, the subjects showed a significant reduction in brain inflammation. Perhaps more importantly, the treatment appeared to restore the brain’s “cellular power plants” (mitochondria), which typically falter with age.
Within weeks, the mice exhibited marked improvements in memory and cognitive function, with effects lasting for several months after treatment.
The implications for human health are profound. While the study is currently in the “bench research” phase (meaning it has not yet transitioned to human clinical trials), it offers a new roadmap for potentially treating age-related conditions like Alzheimer’s disease and general cognitive decline. Because the delivery method is a non-invasive nasal spray rather than a complex surgical procedure, it could eventually become a widely accessible treatment for the “brain fog” that affects millions of aging adults.
Dr. Shetty and his team have already filed a U.S. patent for the therapy, signaling a move toward commercialization. As the global population ages, the “longevity economy” is searching for non-invasive cures for dementia, and this study provides some of the most compelling evidence to date that cognitive decline is not a one-way street.
While the scientific community cautions that results in mice do not always translate to humans, the study adds to a growing body of research exploring how stem-cell-derived therapies might help repair aging brain tissue.
If human trials prove successful, the “fountain of youth” for the human mind may eventually be found in a simple bottle of nasal spray.
